{"ModuleTitle": "Company Description", "CompanyName": "Amicus Therapeutics, Inc.", "Symbol": "FOLD", "Address": "1 CEDAR BROOK DRIVE, CRANBURY, New Jersey, 08512, United States of America", "Phone": "(609) 662-2000", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a global, patient-dedicated biotechnology company focused on discovering,\r\ndeveloping, and delivering novel medicines for rare diseases. We have a\r\nportfolio of product opportunities led by our novel medicine for Fabry disease\r\nthat has achieved widespread global approval, a differentiated biologic for\r\nPompe disease in the clinic, and an industry leading rare disease gene therapy\r\nportfolio.\r\n\r\nThe cornerstone of our portfolio is Galafold\u00ae (also referred to as\r\n\"migalastat\"), the first and only approved oral precision medicine for people\r\nliving with Fabry disease who have amenable genetic variants. Migalastat is\r\ncurrently approved under the trade name Galafold\u00ae in the United States (\"U.S.\"),\r\nEuropean Union (\"E.U.\"), United Kingdom (\"U.K.\"), and Japan, with multiple\r\nadditional approvals granted and applications pending in several geographies\r\naround the world.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0001178879-20-000015.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Bradley Lewis Campbell", "title": "President, Chief Operating Officer & Director"}, {"name": "Daphne E. Quimi", "title": "Chief Financial Officer"}, {"name": "Jay A. Barth", "title": "Chief Medical Officer"}, {"name": "John Francis Crowley", "title": "Chairman & Chief Executive Officer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}